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Manjula Kurella Tamura1,2, Karman Tam1, Eric Vittinghoff3, Dominic Raj4,
Stephen M. Sozio5, Sylvia E. Rosas6, Gail Makos7, Claudia Lora8, Jiang He9, Alan S. Go10,
Chi-yuan Hsu11 and Kristine Yaffe3,12, for the CRIC Study Investigators
1VA Palo Alto Geriatric Research and Education Clinical Center, Palo Alto, California, USA; 2Division of Nephrology, Stanford
University School of Medicine, Palo Alto, California, USA; 3Department of Epidemiology and Biostatistics, University of Cali-
fornia San Francisco, San Francisco, California, USA; 4Division of Renal Disease and Hypertension, GeorgeWashington School
of Medicine, Washington, DC, USA; 5Division of Nephrology, Johns Hopkins University School of Medicine and Welch Center
for Prevention, Epidemiology, and Clinical Research, Baltimore, Maryland, USA; 6Joslin Diabetes Center, Harvard Medical
School, Boston, Massachusetts, USA; 7St. John Providence Medical Center, Detroit, Michigan, USA; 8Division of Nephrology,
University of Illinois College of Medicine, Chicago, Illinois, USA; 9Tulane University School of Public Health and Tropical
Medicine, New Orleans, Louisiana, USA; 10Division of Research, Kaiser Permanente Northern California; Oakland, California,
USA; 11Division of Nephrology, University of California San Francisco, San Francisco, California, USA; and 12Departments of
Psychiatry and Neurology, University of California San Francisco, San Francisco, California, USAIntroduction: Chronic kidney disease (CKD) is associated with an increased risk of cognitive decline, but
the mechanisms remain poorly defined. We sought to determine the relation between serum inflamma-
tory markers and risk of cognitive decline among adults with CKD.
Methods: We studied 757 adults aged $55 years with CKD participating in the Chronic Renal Insufficiency
Cohort Cognitive study. We measured interleukin (IL)1b, IL-1 receptor antagonist, IL-6, tumor necrosis
factor (TNF)a, high-sensitivity C-reactive protein (hs-CRP), and fibrinogen in baseline plasma samples.
We assessed cognitive function at regular intervals in 4 domains and defined incident impairment as a
follow-up score more than 1 SD poorer than the group mean.
Results: The mean age of the sample was 64.3  5.6 years, and the mean follow-up was 6.2  2.5 years. At
baseline, higher levels of each inflammatorymarkerwere associatedwithpoorer age-adjustedperformance.
In analyses adjusted for baseline cognition, demographics, comorbid conditions, and kidney function, par-
ticipants in thehighest tertile of hs-CRP, the highest tertile offibrinogen, and thehighest tertile of IL-1bhadan
increased risk of impairment in attention compared to participants in the lowest tertile of each marker.
Participants in the highest versus lowest tertile of TNF-a had a lower adjusted risk of impairment in executive
function. There was no association between other inflammatory markers and change in cognitive function.
Discussion: Among adults with CKD, higher levels of hs-CRP, fibrinogen, and IL-1b were associated with a
higher risk of impairment in attention. Higher levels of TNF-awere associated with a lower risk of impaired
executive function.
Kidney Int Rep (2017) 2, 192–200; http://dx.doi.org/10.1016/j.ekir.2016.10.007
KEYWORDS: aging; chronic kidney disease; cognitive decline; dementia; epidemiology; inflammation
Published by Elsevier Inc. on behalf of the International Society of Nephrology. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).P atients with chronic kidney disease (CKD) are atincreased risk for cognitive decline and dementia,
particularly cognitive decline associated with a
vascular component.1,2 CKD and dementia share several
risk factors, such as age, diabetes, and hypertension,spondence: Manjula Kurella Tamura, Veterans Affairs Palo
ealth Care System, 3801 Miranda Avenue, Palo Alto, Cali-
94304, USA. E-mail: mktamura@stanford.edu
ved 22 July 2016; revised 11 October 2016; accepted 25
er 2016; published online 31 October 2016suggesting that they have a common pathogenesis. Yet,
in most studies, traditional vascular risk factors do not
appear to attenuate the excess risk of cognitive decline
among patients with CKD.1–3 Inflammation is impli-
cated in many vascular diseases and has been suggested
as a mediator of cognitive decline in patients with CKD.
The nature of the association between inflammation
and CKD may be bidirectional; that is, inflammation
may be both a cause and a consequence of CKD.4,5
Inflammation has also been identified in experi-
mental studies of dementia.6 However, it remainsKidney International Reports (2017) 2, 192–200
M Kurella Tamura et al.: Inflammation and Cognitive Decline in CKD CLINICAL RESEARCHunclear whether systemic inflammation plays a causa-
tive role in the pathogenesis of dementia or whether it
is merely an epiphenomenon, as epidemiologic studies
have produced mixed findings.7–12 Many of these
studies evaluated only 1 or 2 inflammatory markers.
Consequently, they provide an incomplete picture of
the systemic inflammatory state and its relation to
cognitive decline. The intensity of systemic inflamma-
tion, as indicated by elevations in multiple markers of
inflammation, including interleukin-1b (IL-1b),
interleukin-6 (IL-6), tumor necrosis factora (TNF-a),
and C-reactive protein (CRP), appears to increase as
kidney function declines.13,14
Therefore, studying patients with CKD might pro-
vide more specific insight into the relation between
inflammation and cognitive decline related to vascular
causes, as CKD is more strongly associated with
vascular dementia than Alzheimer’s disease.1,2 In 2
cross-sectional studies of patients with CKD, the
inflammatory markers interleukin-10, CRP, and fibrin-
ogen correlated with the presence of cognitive
impairment.15,16 To our knowledge, no studies have
prospectively evaluated the association of systemic
inflammatory markers with cognitive decline among
patients with CKD.
We aimed to determine whether systemic inflam-
matory markers were independently associated with
cognitive decline in patients with CKD. To address
this question, we measured plasma levels of multiple
inflammatory cytokines and acute phase reactants in a
subset of adults enrolled in the Chronic Renal
Insufficiency Cohort (CRIC), a large cohort study of
men and women with CKD. We hypothesized that
elevated levels of inflammatory markers would have
independent, additive effects on the risk of cognitive
decline.
METHODS
Study Design and Recruitment
The CRIC Study is a prospective observational cohort
study designed to evaluate risk factors for progression
of CKD.17,18 From June 2003 through May 2008, we
recruited 3939 persons aged 21 to 74 years from 7
clinical centers across the United States. Participants
met age-based estimated glomerular filtration rate
(eGFR) criteria: 20 to 70 ml/min/1.73 m2 for ages 21 to
44 years, 20 to 60 ml/min/1.73 m2 for ages 45 to
64 years, and 20 to 50 ml/min/1.73 m2 for ages 65 to
74 years. Exclusion criteria included diagnosis of
polycystic kidney disease, pregnancy, recent immu-
nosuppression for kidney disease, coexisting disease
likely to affect survival, prior receipt of dialysis or
organ transplant, residence in nursing homes, or
inability to provide consent. Beginning in 2006, a totalKidney International Reports (2017) 2, 192–200of 825 participants aged 55 years or older from 4 of the
7 CRIC centers were enrolled in a cognitive ancillary
study (the CRIC COG Study). Of these 825 participants,
18 were excluded from the analysis because they had
end-stage renal disease at the CRIC COG baseline visit.
Of the remaining participants, 761 had measurement of
inflammatory markers at baseline and at least 1 cogni-
tive follow-up assessment. We excluded 4 participants
missing important covariates, leaving 757 participants
in the analytic cohort.
Ethics, Consent, and Permissions
Institutional review boards at all clinical sites approved
the study protocol, and all participants provided
written informed consent.
Measurement of Cognitive Function
Participants in CRIC COG underwent a battery of
cognitive function tests.19 Tests were administered
annually for the first 4 years and then biannually
thereafter. The ModifiedMini Mental State Examination
(3MS) is a test of global cognitive function with com-
ponents for concentration, orientation, language, praxis,
and memory.20 The Trailmaking Test A (Trails A) mea-
sures attention, visuospatial scanning, and motor speed.
The Trailmaking Test B (Trails B) primarily assesses ex-
ecutive function.21 The Buschke Selective RemindingTest
measures verbalmemorywith delayed components.22 The
mean follow-up time was 6.2  2.5 years.
Measurement of Inflammatory Markers
Inflammatory markers were measured a median of 1.2
(interquartile ratio [IQR] ¼ 0.9, 2.0) years before the
baseline cognitive assessment. We used high-sensitivity
sandwich enzyme-linked immunosorbent assays to
measure TNF-a, IL-1b, and IL-6 levels, and standard
sandwich enzyme-linked immunosorbent assays to
measure IL-1RA (Quantikine, R&D Systems, Minneap-
olis, MN), as previously described.14 We quantified hs-
CRP and fibrinogen from ethylenediaminetetraacetic
acid (EDTA)treated plasma samples using laser-based
immunonephelometric methods on the BNII nephelom-
eter (Siemens Healthcare, Mountain View, CA). All as-
says were performed in duplicate, and mean values were
used for analysis. Inflammatory markers were analyzed
as tertiles.
Covariates
Sociodemographic and clinical characteristics were
assessed at the cognitive baseline visit. We defined
diabetes by participant self-report, use of medications
for diabetes, or fasting blood glucose of $126 mg/dl.
We defined hypertension by participant self-report,
use of medications for high blood pressure, or a
seated blood pressure of $140/80 mm Hg. We defined193
CLINICAL RESEARCH M Kurella Tamura et al.: Inflammation and Cognitive Decline in CKDcardiovascular disease as participant self-report of a
myocardial infarction, angina, stroke, claudication,
amputation, or revascularization procedure of the
coronaries or the extremities. We defined tobacco
use as current versus former or never use. We calcu-
lated the estimated glomerular filtration rate (eGFR)
with an equation derived from the CRIC Study,
using the annual serum creatinine and cystatin C
measurements corresponding to the first cognitive
function assessment.23 Urine albumin and creatinine
were measured on spot urine samples and categorized
as <30 mg/g, $30 mg/g, or missing for analysis.
Statistical Analysis
Continuous variables were expressed as mean  SD
or median (intertertile range), and categorical variables
were expressed as proportions. We first examined the
age-adjusted baseline association between inflamma-
tory markers and cognitive function, expressed as the
percent difference in cognitive score relative to that of
patients in the lowest tertile of each inflammatory
marker. Next, we determined the association between
inflammatory markers and longitudinal changes in
cognitive scores on each test, using mixed effects
models with unstructured residual correlation matrix
to account for within-subject correlation. Cognitive
test scores were log-transformed for analysis, and then
back-transformed for ease of interpretation. We first
adjusted for age, sex, race, ethnicity, education, and
CRIC clinical center (minimally adjusted model). Next,
we adjusted for baseline comorbid conditions,
including some factors that may lie in the causal
pathway: diabetes, hypertension, cardiovascular dis-
ease, smoking, eGFR, and albuminuria (multivariable
adjusted model). Interactions of inflammatory marker
tertile with time were used to capture the association
of the markers with change in cognitive function,
with a test for linear trend across tertiles. Because the
minimally adjusted and multivariable adjusted models
were similar, multivariable adjusted models are pre-
sented. In sensitivity analyses, we censored observa-
tions after the development of end-stage renal disease.
We also jointly modeled the outcomes of cognitive
decline and time to death or loss to follow-up with
shared random effects, to assess whether informative
censoring of the cognitive function measures materi-
ally changed the results.24
In complementary analyses, we constructed Cox
proportional hazards models to determine the associa-
tion between tertiles of each inflammatory marker and
the incidence of cognitive impairment, defined as a test
score during follow-up more than 1 SD worse than the
group mean at baseline. Individuals with cognitive
impairment at the baseline examination were excluded194from these analyses. Adjusted models included the
baseline cognitive test score in addition to age, sex,
race, ethnicity, education, CRIC clinical center, dia-
betes, hypertension, cardiovascular disease, smoking,
eGFR, and albuminuria. We repeated the models
applying a Bonferroni corrected P value of 0.002 to
account for multiple comparisons (0.05/[6 inflammatory
markers  4 cognitive tests]).
Finally, to assess whether there were additive effects
among the inflammatory markers, we constructed an
inflammatory load score, consisting of the number of
inflammatory markers in the highest tertile. We
compared 2 scores, 1 consisting of IL-1b, hs-CRP, and
fibrinogen, the markers with the strongest associations
with cognitive decline, to a score consisting of all
inflammatory markers.
RESULTS
Baseline Cohort Characteristics
The mean age of the sample was 64.3  5.6 years, and
mean estimated glomerular filtration rate (eGFR) was
43.2  16.3 ml/min/1.73 m2. The sample included 386
men (51.0%), 379 participants of white race/ethnicity
(50.1%), and 383 participants with diabetes (50.6%).
The median and intertertile ranges for each inflam-
matory marker and mean (SD) baseline cognitive test
scores are presented in Table 1. IL-b was correlated
with IL-1 receptor antagonist (IL-1RA) (r ¼ 0.48,
P < 0.01). In addition, hs-CRP was correlated
with fibrinogen (r ¼ 0.38, P < 0.01), and weakly
correlated with IL-1RA (r ¼ 0.12, P < 0.01). There
was no correlation among the other inflammatory
markers.
Higher levels of each inflammatory marker were
associated with poorer age-adjusted cognitive test
scores at baseline (Figure 1). Relative to the scores of
participants in the lowest tertile for each inflammatory
marker, the percentage difference in cognitive test
scores were largest for the 3MS, Trails A tests, and
Trails B tests, and less pronounced for the Buschke
Selective Reminding Test.
Inflammatory Markers and Change in Cognitive
Function
The mean annual percentage change in cognitive func-
tion over 6.2  2.5 years of follow-up was small.
Mean declines in cognitive function were observed
on the 3MS (1.18%, 95% confidence interval
[CI] ¼ 1.92%, 0.44%) and Trails B (0.53%, 95%
CI ¼ 0.92%, 0.13%) tests, whereas cognitive per-
formance improved slightly over time on the Trails A
(0.51%, 95% CI¼ 0.10%, 0.92%) and Buschke (0.82%,
95% CI ¼ 0.38%, 1.27%) tests (Table 2). There was no
significant linear association between tertiles ofKidney International Reports (2017) 2, 192–200
Table 1. Characteristics of 757 CRIC participants with measurement
of inflammatory markers and cognitive function
Characteristic n (%)
Age, yr
50–59 175 (23.1)
60–69 419 (55.4)
$70 163 (21.5)
Sex
Male 386 (51.0)
Female 371 (49.0)
Race
White 379 (50.1)
Black 325 (42.9)
Other/unknown 53 (7.0)
Hispanic ethnicity
Hispanic 21 (2.8)
Other/unknown 736 (97.2)
Education
<High school 108 (14.3)
High school graduate 155 (20.5)
Some college 494 (65.3)
Diabetes mellitus 383 (50.6)
Hypertension 687 (90.8)
Prior cardiovascular disease 290 (38.3)
Current smoker 79 (10.4)
eGFR CRIC, ml/min/1.73 m2
$60 124 (16.4)
45 to <60 211 (27.9)
30 to <45 255 (33.7)
<30 167 (22.1)
Albuminuria (mg/g)
<30 351 (46.4)
>30 381 (50.3)
Unknown 25 (3.3)
Inflammatory markers Median (P33, P67)
IL-1b (pg/ml) 0.06 (0.06, 0.48)
IL-1RA (pg/ml) 634.1 (422.7, 1026.8)
TNF-a (pg/ml) 2.00 (1.60, 2.60)
IL-6 (pg/ml) 1.92 (1.39, 2.52)
hs-CRP (mg/L) 2.47 (1.35, 4.41)
Fibrinogen (g/L) 4.00 (3.59, 4.45)
Cognitive function Mean (SD)
3MS 93.15 (7.36)
Trails A 54.29 (36.57)
Trails B 136.95 (77.68)
Buschke Selective Reminding Test 7.44 (2.93)
CRIC, Chronic Renal Insufficiency Cohort; eGFR, estimated glomerular filtration rate;
hs-CRP, high sensitivity C-reactive protein; IL, interleukin; 3MS, Modified Mini Mental
State Examination; TNF, tumor necrosis factor.
Note: Inflammatory markers are presented as median (33rd, 67th) percentiles.
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in minimally adjusted models (Supplementary Table S1).
In multivariable adjusted models, there was a significant
linear trend for larger improvement on the Buschkewith
higher levels of fibrinogen (Table 2). There was no evi-
dence for a linear trend across inflammatory marker
tertiles on other cognitive tests. Compared to partici-
pants in the lowest tertile, participants with IL-1RA
levels in the middle tertile experienced more rapid
cognitive decline on the 3MS, but this did not reachKidney International Reports (2017) 2, 192–200statistical significance for participants in the highest
tertile of IL-1RA. Compared to participants in the lowest
tertile, participants in the middle tertile of TNF-a
experienced significantly slower decline on the 3MS, but
this did not reach significance for participants in the
highest tertile. We observed a similar pattern in models
censoring patients at end-stage renal disease and in joint
models for change in cognitive function and time to
death or loss to follow-up (Supplementary Table S2).
Inflammatory Markers and Incident Cognitive
Impairment
During follow-up, the incidence of impairment ranged
between 13.1% on the Trails A test to 19.8% on the
Trails B test (Table 3). The associations between
inflammatory markers and incident cognitive impair-
ment were consistent with the direction of the parameter
estimates from the models evaluating change in cogni-
tive function. In multivariable adjusted models, partic-
ipants with hs-CRP in the highest tertile, and
participants with fibrinogen levels in the highest tertile
had more than a 2-fold higher adjusted risk of incident
impairment on the Trails A test compared to participants
in the lowest tertile of each marker. In addition, partic-
ipants in the highest tertile of IL-1b had a borderline
nonsignificant increased risk of impairment on the Trails
A compared to participants in the lowest tertile.
Compared to participants in the lowest tertile of IL-1RA,
participants with IL-1RA levels in the middle tertile had
a borderline nonsignificant higher adjusted risk of
incident impairment on the 3MS, but this did not reach
significance for participants in the highest tertile.
Conversely, participantswith TNF-a levels in the second
or third tertile had a lower adjusted risk of incident
impairment on the Trails B test compared to participants
in the lowest tertile. These associations were not statis-
tically significant after accounting for multiple com-
parisons (Supplementary Table S3).
Compared to participants without elevated levels of
IL-1b, hs-CRP, or fibrinogen, there was a borderline
higher risk of impairment on the Trails A test for par-
ticipants with 1 elevated marker (hazard ratio [HR] ¼
1.72, 95% CI¼ 0.91, 3.26), and significantly higher risk
for participants with 2 or more elevated inflammatory
markers (HR ¼ 3.21, 95% CI ¼ 1.71, 6.01) after adjust-
ment for baseline cognitive function, demographic
characteristics, comorbid conditions, and kidney func-
tion. There was no significant association between
inflammatory load and other cognitive tests. In com-
parison, when the inflammatory load score included all
inflammatory markers, the risk of impairment on the
Trails A test was significantly higher for participants
with 2 elevated inflammatory markers (HR ¼ 2.35, 95%
CI ¼ 1.06, 5.22), and 3 or more elevated inflammatory195
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Figure 1. Adjusted percent difference in baseline cognitive scores by inflammatory marker.
CLINICAL RESEARCH M Kurella Tamura et al.: Inflammation and Cognitive Decline in CKDmarkers (HR ¼ 2.32, 95% CI ¼ 1.07, 5.04), compared to
participants with no elevated inflammatory markers.
DISCUSSION
In a large cohort of adults with CKD, higher levels of
multiple systemic inflammatory markers were associ-
ated with poorer baseline cognitive function. In lon-
gitudinal analyses, the association between systemic
inflammatory markers and mean change in cognitive
function was small. The strongest associations
between inflammatory markers and change in cogni-
tive function were observed in the domain of atten-
tion, assessed with the Trails A test. Participants with196the highest levels of hs-CRP or fibrinogen each had
more than a 2-fold increased risk of impairment in
attention compared to participants with the lowest
levels, independent of multiple potential confounders,
whereas participants in the highest tertile of IL-1b had
a similar but nonsignificant higher risk of impairment
in attention. In addition, participants with elevated
levels of 2 or more of these inflammatory markers had
more than a 3-fold increased risk of impairment in
attention. Perhaps unexpectedly, participants with
higher levels of TNF-a were at lower risk for
impairment in executive function, assessed with the
Trails B test.Kidney International Reports (2017) 2, 192–200
Table 2. Adjusted association of inflammatory markers with change in cognitive function
Parameter estimate (95% confidence interval)
3MS Trails A Trails B Buschke Selective Reminding
Mean annual change, % –1.18 (–1.92, –0.44) 0.51 (0.10, 0.92) –0.53 (–0.92, –0.13) 0.82 (0.38, 1.27)
IL-1b, pg/ml
Tertile 2  time 0.17 (–1.97, 2.26) 1.05 (–0.16, 2.25) –0.08 (–1.28, 1.11) 0.31 (–1.02, 1.66)
Tertile 3  time –1.13 (–2.90, 0.60) –0.30 (–1.30, 0.69) 0.01 (–0.96, 0.98) –0.25 (–1.32, 0.83)
P value for trend 0.20 0.55 0.98 0.64
IL-1RA, pg/ml
Tertile 2  time --2.17 (--3.97, --0.41) 0.23 (–0.78, 1.22) 0.55 (–0.43, 1.52) –0.16 (–1.25, 0.94)
Tertile 3  time –1.50 (–3.36, 0.32) –0.40 (–1.45, 0.64) 0.10 (–0.92, 1.11) –0.43 (–1.56, 0.71)
P value for trend 0.11 0.45 0.85 0.46
TNF-a, pg/ml
Tertile 2  time 1.82 (0.04, 3.56) 0.41 (–0.62, 1.42) 0.40 (–0.60, 1.39) 0.65 (–0.46, 1.77)
Tertile 3  time 1.31 (–0.66, 3.23) 0.48 (–0.65, 1.60) 0.28 (–0.82, 1.38) 0.75 (–0.48, 1.99)
P value for trend 0.19 0.40 0.61 0.23
IL-6, pg/ml
Tertile 2  time 0.53 (–1.28, 2.30) –0.47 (–1.50, 0.56) –0.54 (–1.55, 0.46) –0.23 (–1.35, 0.89)
Tertile 3  time 0.12 (–1.81, 2.01) –0.32 (–1.42, 0.77) –0.01 (–1.08, 1.05) 0.56 (–0.62, 1.76)
P value for trend 0.91 0.57 0.99 0.36
hs-CRP (mg/L)
Tertile 2  time –0.38 (–2.12, 1.34) –0.52 (–1.51, 0.46) –0.56 (–1.53, 0.40) –0.50 (–1.56, 0.57)
Tertile 3  time –1.23 (–3.08, 0.57) –0.19 (–1.23, 0.84) 0.15 (–0.87, 1.15) 0.15 (–0.98, 1.28)
P value for trend 0.18 0.72 0.78 0.80
Fibrinogen, g/l
Tertile 2  time 0.02 (–1.73, 1.74) 0.03 (–0.97, 1.01) 0.42 (–0.54, 1.37) 0.37 (–0.71, 1.45)
Tertile 3  time 0.02 (–1.89, 1.89) –0.66 (–1.76, 0.42) 0.22 (–0.84, 1.26) 1.37 (0.19, 2.58)
P value for trend 0.98 0.23 0.69 0.02
hs-CRP, high sensitivity C-reactive protein; IL, interleukin; 3MS, Modified Mini Mental State Examination; TNF, tumor necrosis factor.
Parameter estimates represent percent change in cognitive function tests per year, relative to the referent group in the lowest tertile of each inflammatory marker. A negative parameter
estimate indicates poorer cognitive function over time relative to the referent group.
Models are adjusted for age, sex, race, ethnicity, education, Chronic Renal Insufficiency Cohort (CRIC) center, diabetes, hypertension, cardiovascular disease, smoking, estimated
glomerular filtration rate, and albuminuria. Parameter estimates in bold are statistically significant (P < 0.05).
M Kurella Tamura et al.: Inflammation and Cognitive Decline in CKD CLINICAL RESEARCHSome aspects of our study warrant consideration
when interpreting these results. We assessed change in
cognitive function in 2 ways: as a continuous measure
and as a dichotomous outcome incident cognitive
impairment, the latter to capture large declines in
cognitive function that are likely to be clinically
important. Although the 2 approaches yielded results
that were generally consistent, several inflammatory
markers had stronger associations with incident
impairment than with change in cognitive function, a
result that is similar to a previous study of inflamma-
tory markers in patients without CKD.8 This might
imply that the association between inflammation and
cognitive decline is not uniform across the spectrum of
cognitive function. Along the same lines, measurement
error may have a larger relative effect on small changes
in cognitive function.8 Participants with high levels of
inflammatory markers may also be at higher risk for
death, which might lead to an underestimation of the
association between inflammatory markers and change
in cognitive function. However, our findings were
robust to analyses that accounted for death or follow-
up loss. We assessed each cognitive test as a separate
outcome because each taps a different cognitiveKidney International Reports (2017) 2, 192–200domain. This approach allowed us to evaluate whether
inflammatory markers were associated with decline in
specific domains, but increases the likelihood of a false-
positive finding. When we used the Bonferroni method
to account for multiple comparison, the findings did
not reach statistical significance; thus the positive
findings in the main analysis should be interpreted
with caution. This method of correcting for multiple
comparisons has been criticized for being too conser-
vative, because it assumes that the outcomes are
independent.
The most studied inflammatory marker is the acute
phase reactant CRP. In a meta-analysis of 7 studies in
populations without CKD, higher levels of CRP were
associated with an increased risk of dementia,
including vascular dementia.25 Several but not all
studies in the general population have also demon-
strated a relationship between elevated CRP levels and
cognitive decline.9,10 In a cross-sectional study of
Mexican Americans with CKD, Szerlip et al. found that
a serum proteomic profile including CRP was correlated
with the prevalence of cognitive impairment; however,
the strength of the association for CRP individually was
not reported.15197
Table 3. Adjusted risk of incident cognitive impairment among adults with chronic kidney disease
Hazard ratio (95% confidence interval)
3MS Trails A Trails B Buschke Selective Reminding
n (%) with impairment 92 (13.9) 85 (13.1) 121 (19.8) 105 (16.9)
IL-1b, pg/ml
Tertile 1 (Ref) 1 1 1 1
Tertile 2 0.86 (0.43, 1.72) 1.16 (0.59, 2.29) 0.63 (0.31, 1.27) 1.18 (0.62, 2.23)
Tertile 3 1.02 (0.60, 1.75) 1.67 (0.97, 2.89) 0.92 (0.57, 1.46) 1.05 (0.64, 1.72)
IL-1RA, pg/ml
Tertile 1 (Ref) 1 1 1 1
Tertile 2 1.75 (0.99, 3.10) 1.13 (0.63, 2.03) 1.09 (0.66, 1.78) 1.48 (0.89, 2.45)
Tertile 3 1.26 (0.69, 2.31) 1.37 (0.73, 2.55) 1.05 (0.62, 1.78) 1.56 (0.91, 2.65)
TNF-a, pg/ml
Tertile 1 (Ref) 1 1 1 1
Tertile 2 0.92 (0.50, 1.70) 1.47 (0.74, 2.90) 0.56 (0.34, 0.91) 0.98 (0.55, 1.77)
Tertile 3 1.44 (0.75, 2.76) 1.52 (0.74, 3.14) 0.47 (0.27, 0.84) 1.17 (0.64, 2.14)
IL-6, pg/ml
Tertile 1 (Ref) 1 1 1 1
Tertile 2 1.32 (0.73, 2.39) 1.08 (0.57, 2.08) 1.38 (0.81, 2.34) 1.13 (0.66, 1.95)
Tertile 3 1.18 (0.63, 2.22) 1.08 (0.56, 2.10) 1.33 (0.77, 2.31) 1.02 (0.58, 1.80)
hs-CRP, mg/l
Tertile 1 (Ref) 1 1 1 1
Tertile 2 1.06 (0.60, 1.87) 0.81 (0.43, 1.51) 1.23 (0.75, 2.02) 1.61 (0.98, 2.64)
Tertile 3 1.45 (0.83, 2.53) 2.27 (1.26, 4.06) 1.29 (0.78, 2.15) 1.09 (0.65, 1.84)
Fibrinogen, g/l
Tertile 1 (Ref) 1 1 1 1
Tertile 2 0.83 (0.48, 1.44) 1.17 (0.60, 2.29) 0.92 (0.55, 1.52) 1.20 (0.72, 1.99)
Tertile 3 0.73 (0.40, 1.33) 2.06 (1.10, 3.84) 1.17 (0.71, 1.93) 0.82 (0.47, 1.45)
hsCRP, high-sensitivity C-reactive protein; IL, interleukin; 3MS, Modified Mini Mental State Examination; Ref, reference; TNF, tumor necrosis factor.
Models are adjusted for baseline cognitive score, age, sex, race, ethnicity, education, Chronic Renal Insufficiency Cohort (CRIC) center, diabetes, hypertension, cardiovascular disease,
smoking, estimated glomerular filtration rate, and albuminuria. Hazard ratios in bold are statistically significant (P < 0.05).
CLINICAL RESEARCH M Kurella Tamura et al.: Inflammation and Cognitive Decline in CKDFibrinogen is an acute phase reactant involved in the
coagulation cascade. Like CRP, elevated fibrinogen
levels have been linked to cognitive decline and
dementia, including vascular dementia, in populations
without CKD.26,27 Seidel et al. reported that elevated
fibrinogen levels were cross-sectionally correlated with
cognitive impairment in a cohort of 119 patients with
CKD.16
Our results extend the findings from prior studies,
by demonstrating that CRP and fibrinogen are inde-
pendently associated with longitudinal changes in
some domains of cognitive function in patients with
CKD. Our results suggest that elevated CRP, fibrinogen,
and possibly IL-1b levels are more strongly associated
with incident impairment in attention versus global
cognition or memory (assessed in the current study
with the 3MS and Buschke tests, respectively). This
observation may be due to chance. Alternatively, it
may be consistent with the hypothesis that inflamma-
tion contributes to cognitive decline in part through
vascular mechanisms, as impaired attention is more
prominent in vascular causes of dementia than memory
impairment.6
In addition, we found that higher levels of the
inflammatory cytokine TNF-a were associated with a
lower risk of impairment in executive function. Among198patients without CKD, the relation between TNF-a and
cognitive decline has been conflicting; although 1
study demonstrated an association between increased
peripheral blood mononuclear cell production of TNF-a
and an increased risk of dementia (specifically Alz-
heimer’s disease), other studies have not identified an
association between TNF-a and cognitive decline.9,12
To test the hypothesis that inflammatory markers
have additive effects on cognitive function, we con-
structed an inflammatory load score as a proxy for the
systemic inflammatory state. These results suggest that
IL-1b, hs-CRP, and fibrinogen may have independent,
additive effects on the risk of impairment in attention.
When the inflammatory load included all 6 inflamma-
tory markers, this association was attenuated, sug-
gesting that IL-1RA, IL-6, and TNF-a did not have
additive effects on the risk of impairment after
accounting for IL-1b, hs-CRP, and fibrinogen.
Strengths of this study include the prospective
design, diverse study population, use of a cognitive
battery to assess cognitive function, and measurement
of multiple inflammatory markers, providing a more
complete picture of the systemic inflammatory state.
This study also has several limitations. Participants
in CRIC may be at lower risk for cognitive decline than
the broader population with CKD, because they areKidney International Reports (2017) 2, 192–200
M Kurella Tamura et al.: Inflammation and Cognitive Decline in CKD CLINICAL RESEARCHselected for the ability to comply with study visits and
they may be more motivated to pursue healthy
behaviors. Inflammatory markers were measured at a
single point in time, a median 1.2 years before the
baseline cognitive test assessment. This lag may have
caused a larger relationship between inflammatory
markers and changes in cognitive function to go
unobserved. We cannot rule out the possibility that the
results reflect false-positive findings from conducting
multiple comparisons, as the findings did not reach
significance using a conservative method to account for
multiple comparisons. Finally, because this was an
observational study, residual confounding may have
affected the results.
In conclusion, in a large cohort of adults with CKD,we
found that elevated levels of multiple inflammatory
markers were associated with an increased risk of
impairment in attention, whereas elevated levels of TNF-
awere associatedwith a lower risk of impaired executive
function. Additional studies are needed to confirm these
results, and to determine whether treatment of inflam-
mation can slow or prevent cognitive decline.
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